F-18-OMFD-PET for Radiotherapy Treatment Planning and Evaluation of Early Therapy Response
NCT ID: NCT00180193
Last Updated: 2009-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
40 participants
OBSERVATIONAL
2003-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tumor Metabolism of Lung Cancer in Patients Who Underwent Percutaneous Radiation Measured With F-18-FDG-PET
NCT00180154
Study on Amino Acid Uptake in Brain Tumors
NCT00204295
Tumor Metabolism of Head and Neck Cancer in Patients Who Underwent Radiation Therapy Measured With F-18-FDG-PET
NCT00180245
18F ML-10 for Early Detection of Response of Brain Metastases to WBRT
NCT00791063
Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme
NCT01873469
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Radiation therapy indicated
* Written consent
Exclusion Criteria
* Mental impairment
* Drug/alcohol abuse
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Advanced Biochemical Compounds GmbH
INDUSTRY
Technische Universität Dresden
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Klinik und Poliklinik für Nuklearmedizin
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joerg Kotzerke, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Nuclear Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Nuclear Medicine
Dresden, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ABX-OMFD-FU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.